```mermaid
flowchart TD
NF2EL2["NF2EL2<br/>(NRF2 gene)"] -->|"encodes"| NRF2["NRF2<br/>(Master antioxidant<br/>transcription factor)"]
KEAP1_gene["KEAP1<br/>(gene)"] -->|"encodes"| KEAP1["KEAP1<br/>(Kelch-like ECH-associated<br/>protein 1)"]
KEAP1 -->|"inhibits"| NRF2
NRF2 -->|"inhibits"| KEAP1
kaempferol["Kaempferol<br/>(Natural activator)"] -->|"activates"| NRF2
PGC1A["PGC-1alpha<br/>(Metabolic regulator)"] -->|"activates"| NRF2
TGR5["TGR5<br/>(G-protein coupled<br/>receptor)"] -->|"activates"| NRF2
ML385["ML385<br/>(NRF2 inhibitor)"] -->|"inhibits"| NRF2
NRF2 -->|"activates"| ARE["ARE<br/>(Antioxidant Response<br/>Elements)"]
ARE -->|"transcriptional<br/>activation"| HMOX1["HMOX1<br/>(Heme oxygenase-1)"]
ARE -->|"transcriptional<br/>activation"| NQO1["NQO1<br/>(NAD(P)H quinone<br/>oxidoreductase)"]
ARE -->|"transcriptional<br/>activation"| GCLC["GCLC/GCLM<br/>(Glutathione synthesis<br/>enzymes)"]
ARE -->|"transcriptional<br/>activation"| SLC7A11["SLC7A11<br/>(Cystine/glutamate<br/>antiporter)"]
NRF2 -->|"regulates"| SOD["SOD<br/>(Superoxide<br/>dismutase)"]
NRF2 -->|"regulates"| CATALASE["Catalase<br/>(H2O2 detoxification)"]
HMOX1 -->|"reduces"| OXIDATIVE_STRESS["Oxidative Stress<br/>(Neuronal damage)"]
GCLC -->|"produces"| REDOX_HOMEOSTASIS["Redox Homeostasis<br/>(Cellular protection)"]
SOD -->|"maintains"| REDOX_HOMEOSTASIS
CATALASE -->|"maintains"| REDOX_HOMEOSTASIS
REDOX_HOMEOSTASIS -->|"protects against"| NEU
Nrf2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
title: NRF2 Gene
<div class="infobox .infobox-gene">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.1em;">NRF2</th></tr>
<tr><td><b>Full Name</b></td><td>Nuclear Factor Erythroid 2-Related Factor 2</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>2q31.3</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[4780](https://www.ncbi.nlm.nih.gov/gene/4780)</td></tr>
<tr><td><b>OMIM</b></td><td>[606008](https://www.omim.org/entry/606008)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>[ENSG00000116044](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116044)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q16236](https://www.uniprot.org/uniprot/Q16236)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">ATHEROSCLEROSIS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2185 edges</a></td>
</tr>
</table>
</div>
NFE2L2 (commonly known as NRF2) is the master regulator of antioxidant response and cellular defense against oxidative stress. It is a critical therapeutic target for neurodegenerative diseases characterized by oxidative damage. By activating over 200 target genes, NRF2 coordinates the cellular defense against reactive oxygen species (ROS), electrophiles, and xenobiotics[@nrf2020].
The NRF2 gene (NFE2L2) spans approximately 22 kb on chromosome 2q31.3 and contains 5 exons. The NRF2 protein contains 605 amino acids and is characterized by several functional domains:
NRF2 is a basic leucine zipper (bZIP) transcription factor. Under homeostatic conditions, NRF2 is sequestered in the cytoplasm by KEAP1 (Kelch-like ECH-associated protein 1), which acts as an adaptor for the Cullin 3-based E3 ubiquitin ligase complex. KEAP1 senses oxidative stress through its cysteine residues (C151, C273, C288), leading to NRF2 release and nuclear translocation[@keapnrf2021].
Under basal conditions, NRF2 is constantly ubiquitinated and degraded by the proteasome. Upon oxidative or electrophilic stress, KEAP1 cysteine residues are modified, preventing NRF2 degradation. Stabilized NRF2 translocates to the nucleus, heterodimerizes with small Maf proteins, and binds to the Antioxidant Response Element (ARE: 5'-TGACnnnGC-3') in the promoter regions of target genes.
NRF2 regulates genes involved in:
| Category | Key Genes | Function |
|----------|-----------|----------|
| Phase I Metabolism | NQO1, NQO2 | Quinone detoxification |
| Phase II Metabolism | GSTP1, GSTA2, UGT1A1 | Glutathione conjugation, glucuronidation |
| Antioxidant Defense | HMOX1, SOD1, CAT, GPX1 | Heme oxygenase, [ROS](/entities/reactive-oxygen-species) scavenging |
| Glutathione Metabolism | GCLC, GCLM, GSS | Glutathione synthesis |
| Drug Efflux | ABCC1, ABCC2 | Multidrug resistance proteins |
| Proteostasis | SQSTM1 (p62), HSP70 | [Autophagy](/entities/autophagy), protein quality control |
| Mitochondrial Function | PGC-1α, TFAM | Mitochondrial biogenesis |
NRF2 exerts anti-inflammatory effects through:
NRF2 activation is protective in AD through multiple mechanisms[@nrf2020a]:
NRF2 is a major therapeutic target in PD due to:
In HD, NRF2 dysregulation contributes to disease progression:
NRF2 alterations in ALS include:
NRF2 plays protective roles in MS:
NRF2 activation is protective in ischemic stroke:
NRF2 is expressed in neurons and glia throughout the brain:
| Cell Type | Expression Level | Key Functions |
|-----------|-----------------|---------------|
| [Neurons](/entities/neurons) | Moderate-High | Antioxidant defense, synaptic protection |
| [Astrocytes](/entities/astrocytes) | High | Detoxification, glutathione production |
| [Microglia](/entities/microglia) | Moderate | Inflammatory regulation |
| Oligodendrocytes | Moderate | Myelin protection |
| Endothelial Cells | Moderate | BBB protection |
High Expression Regions: Cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus) (CA1-CA3, dentate gyrus), basal ganglia (striatum, substantia nigra), cerebellum (Purkinje cells), spinal cord motor neurons.
Expression is inducible by oxidative stress, electrophiles, and neurotrophic factors (BDNF, NGF).
| Compound | Mechanism | Clinical Status | Diseases |
|----------|-----------|-----------------|----------|
| Sulforaphane | Covalent KEAP1 modification | Phase II trials | AD, PD, schizophrenia |
| Bardoxolone Methyl | KEAP1-NRF2 activation | Phase II/III trials | CKD, Friedreich's ataxia |
| Dimethyl Fumarate | KEAP1 modification | Approved (MS, psoriasis) | MS, ALS |
| Oltipraz | KEAP1 modification | Phase II trials | Liver disease, cancer chemoprevention |
| CDDO-Me | Covalent KEAP1 modification | Phase II trials | Diabetes, CKD |
| Resveratrol | NRF2 activation | Various trials | AD, CVD |
[@nrf2020]: The NRF2 regulatory network and its dysregulation in toxicity, injury, and disease. Annu Rev Pharmacol Toxicol. 2020;60:401-427. PMID: 31415175(https://pubmed.ncbi.nlm.nih.gov/31415175/)
[@keapnrf2021]: KEAP1-NRF2 signaling in the heart: From basic science to clinical translation. Nat Rev Cardiol. 2021;18(12):759-774. PMID: 34267371(https://pubmed.ncbi.nlm.nih.gov/34267371/)
[@nrf2020a]: NRF2 as a therapeutic target in neurodegenerative diseases. Neurotherapeutics. 2020;17(1):62-80. PMID: 31808092(https://pubmed.ncbi.nlm.nih.gov/31808092/)
[@nrf2019]: NRF2 activation protects against oxidative stress and dopaminergic neuron loss in Parkinson's disease models. Nat Neurosci. 2019;22(8):1246-1258. PMID: 31391549(https://pubmed.ncbi.nlm.nih.gov/31391549/)
The study of Nrf2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving NRF2 Gene discovered through SciDEX knowledge graph analysis: